CN109223582A - Diol type ginsenoside nano-emulsion with anti aging effect function and preparation method thereof - Google Patents
Diol type ginsenoside nano-emulsion with anti aging effect function and preparation method thereof Download PDFInfo
- Publication number
- CN109223582A CN109223582A CN201811282724.4A CN201811282724A CN109223582A CN 109223582 A CN109223582 A CN 109223582A CN 201811282724 A CN201811282724 A CN 201811282724A CN 109223582 A CN109223582 A CN 109223582A
- Authority
- CN
- China
- Prior art keywords
- diol type
- type ginsenoside
- ginsenoside
- diol
- emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930182494 ginsenoside Natural products 0.000 title claims abstract description 150
- 229940089161 ginsenoside Drugs 0.000 title claims abstract description 146
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 14
- 150000002009 diols Chemical class 0.000 title claims description 117
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 76
- 239000000284 extract Substances 0.000 claims abstract description 54
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 67
- 239000011259 mixed solution Substances 0.000 claims description 32
- 235000019441 ethanol Nutrition 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 22
- 241000208340 Araliaceae Species 0.000 claims description 16
- 235000008434 ginseng Nutrition 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 14
- 238000010828 elution Methods 0.000 claims description 14
- NWGKJDSIEKMTRX-MDZDMXLPSA-N Sorbitan oleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)C1OCC(O)C1O NWGKJDSIEKMTRX-MDZDMXLPSA-N 0.000 claims description 13
- 239000002537 cosmetic Substances 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 6
- -1 palmitinic acid isopropyl Ester Chemical class 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims description 2
- 150000002338 glycosides Chemical class 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 abstract description 7
- 108010035532 Collagen Proteins 0.000 abstract description 7
- 229920001436 collagen Polymers 0.000 abstract description 7
- 239000002245 particle Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 102000029816 Collagenase Human genes 0.000 abstract description 2
- 108060005980 Collagenase Proteins 0.000 abstract description 2
- 229960002424 collagenase Drugs 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 64
- 238000010438 heat treatment Methods 0.000 description 19
- 238000003760 magnetic stirring Methods 0.000 description 18
- 239000003921 oil Substances 0.000 description 12
- 239000002994 raw material Substances 0.000 description 10
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 9
- 229930182490 saponin Natural products 0.000 description 9
- 235000017709 saponins Nutrition 0.000 description 9
- 238000005259 measurement Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000002250 absorbent Substances 0.000 description 6
- 230000002745 absorbent Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 4
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 4
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000002137 ultrasound extraction Methods 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 2
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种二醇型人参皂苷纳米乳及其制备方法和用途。该二醇型人参皂苷纳米乳由如下组分组成：由二醇型人参皂苷提取物和水组成的水相、油相和混合乳化剂；其中，所述水相和油相的质量比为5～8：45，所述油相和混合乳化剂的质量比为7.5～8：2～2.5，所述二醇型人参皂苷提取物在水相中的质量浓度为15～25％，所述二醇型人参皂苷提取物含有的二醇型人参皂苷Rb1、Rb2、Rc和Rd的含量之和不低于38％。所制备的二醇型人参皂苷纳米乳粒度符合要求，具有很好的皮肤透过性能和皮肤滞留性能，并可通过促进胶原蛋白合成，抑制胶原蛋白酶活性，以达到抗皮肤衰老功能。The invention discloses a diol-type ginsenoside nanoemulsion and a preparation method and application thereof. The glycol-type ginsenoside nanoemulsion is composed of the following components: a water phase, an oil phase and a mixed emulsifier composed of a glycol-type ginsenoside extract and water; wherein, the mass ratio of the water phase and the oil phase is 5 ~8:45, the mass ratio of the oil phase and the mixed emulsifier is 7.5-8:2-2.5, the mass concentration of the diol-type ginsenoside extract in the water phase is 15-25%, and the two The total content of glycol-type ginsenosides Rb 1 , Rb 2 , Rc and Rd contained in the alcohol-type ginsenoside extract is not less than 38%. The prepared diol-type ginsenoside nanoemulsion meets the requirements in particle size, has good skin permeation performance and skin retention performance, and can achieve anti-aging function by promoting collagen synthesis and inhibiting collagenase activity.
Description
Technical field
The present invention relates to a kind of nanoemulsions and its preparation method and application, and in particular to anti aging effect function
Diol type ginsenoside nano-emulsion and preparation method thereof.
Background technique
Ginseng is Araliaceae herbaceos perennial (Panax ginseng, C.A.Mey.), containing amino acid, vitamin,
It is polysaccharide, ginseng essential oil, inorganic elements, alkaloid, peptide matters, fats, saponin(e, organic acid, flavonoids, sterol, wooden
The various chemical components such as element, enzyme, wherein ginsenoside is the main active constituent of ginseng.According to the difference of ginsengenin,
Ginsenoside is divided into oleanolic acid saponins, protopanaxatriol saponins and protopanoxadiol saponins.Diol type ginseng soap
Glycosides curative effect with highly significant in terms of anticancer, anti-aging, tonifying primordial Qi, enhancing Abwehrkraft des Koepers, improvement.In recent years
Come, since the effect of diol type ginsenoside is in terms of anti-aging is significant, is applied to drug and cosmetic field to reach
The research of anti aging effect becomes a popular research.But diol type ginsenoside polarity is big, fat-soluble difference, is not easy through skin
Skin, so bringing a very hang-up to dermatologic.
Summary of the invention
Deficiency in view of panoxadiol type ginsenoside extract described above as product, it is an object of the invention to
There is provided a kind of diol type ginsenoside nano-emulsion using diol type ginsenoside as raw material, with anti aging effect function and its
Preparation method.
A kind of diol type ginsenoside nano-emulsion, is grouped as by following group: by diol type ginsenoside extract and water group
At water phase, oil mutually and blended emulsifier；Wherein, the mass ratio of the water phase and oily phase is 5~8:45, the oil phase and mixing
The mass ratio of emulsifier is 7.5~8:2~2.5, and mass concentration of the diol type ginsenoside extract in water phase is 15
~25%, the diol type ginsenoside Rb that the diol type ginsenoside extract contains1、Rb2, Rc and Rd the sum of content no
Lower than 38%.
In the above-mentioned technical solutions, the oil is mutually isopropyl palmitate or isopropyl myristate, the mixing cream
Agent is obtained by sorbester p17 and 1,2- propylene glycol 3:1 in mass ratio~3 configuration.
In the above-mentioned technical solutions, the preparation method of the diol type ginsenoside extract includes the following steps:
(1) Ca (OH) for being 11~13 by ginseng coarse powder and pH2Aqueous solution in solid-liquid ratio g:mL=1:10~15 ratio
Mixing is 20 DEG C~35 DEG C in Extracting temperature, extracts under conditions of ultrasonic power 120w~160w, extracting solution filtering obtains
Ginsenoside extracting solution；
(2) the ginsenoside extracting solution for obtaining step (1) is first eluted with water, is then used by large pore resin absorption column
The ethanol gradient elution that concentration expressed in percentage by volume is 35%~85%, collects eluent, and concentration, freeze-drying obtain diol type ginseng
Saponin extract.
In the above-mentioned technical solutions, the preparation method of the diol type ginsenoside extract includes the following steps:
(1) Ca (OH) for being 13 by ginseng coarse powder and pH2Aqueous solution is mixed in the ratio of solid-liquid ratio g:mL=1:10, is being mentioned
Taking temperature is 20 DEG C, is extracted under conditions of ultrasonic extraction power 160w, and extracting solution filtering obtains ginsenoside extracting solution；
(2) the ginsenoside extracting solution for obtaining step (1) is by large pore resin absorption column, with the water of 3~6 times of column volumes
Elution, then successively with 35% ethyl alcohol of 3~6 times of column volumes, 85% ethanol elution of 3~6 times of column volumes, 85% ethyl alcohol of collection
Eluent, concentration, freeze-drying, obtains diol type ginsenoside extract.
In the above-mentioned technical solutions, in step (2), first with the water elution of 3~6 times of column volumes, then successively with 3~6
35% ethyl alcohol of times column volume, 60% ethyl alcohol of 3~6 times of column volumes, 3~6 times of column volumes 85% ethanol elution, collect 85%
Ethanol eluate, it is concentrated, be freeze-dried diol type ginsenoside extract dry product.
In the present invention, ginsenoside extracting solution that step (1) is obtained is adsorbed by large pore resin absorption column, stand 2h with
On, so that the nonpolarity such as ginsenoside and low pole ingredient is sufficiently adsorbed in macroporous absorbent resin, later, is first eluted with water, with
Remove unadsorbed most of polar impurity；Then miscellaneous to remove three alcohol type ginsenosides and small part with 35% ethanol elution
Matter；Other type ginsenosides and impurity are further removed with 60% ethanol elution again later, to improve the diol type in extract
The purity of ginsenoside, the present invention in the step can omit；Finally with 85% ethanol elution, to collect diol type ginsenoside,
Mainly contain Rb1、Rb2, Rc and tetra- kinds of Rd, the sum of content is not less than the 38% of total extract amount.
In the above-mentioned technical solutions, in step (1), in the extraction step, extraction time is 1~3 time, is mentioned every time
Taking the time is 20~60min, preferably 20min.
In the above-mentioned technical solutions, in step (2), by the ginsenoside extracting solution, filtering, filtrate is concentrated into leaching
Cream is added the dissolution of 80% ethyl alcohol, is filtered to obtain ginsenoside filtrate；The concentration of ginsenoside filtrate removes ethyl alcohol, and distilled water is added
Dissolution obtains ginsenoside aqueous solution, and aqueous solution is with the rate of 0.2~0.3mL/s of flow velocity by being washed with water in advance to no ethanol flavor
Large pore resin absorption column, 2h or more can be placed after upper prop, so that the ingredients such as ginsenoside in filtrate sufficiently adsorb
In on macroporous absorbent resin.The macroporous absorbent resin preferably uses macroporous absorbent resin D101.
The present invention also provides the preparation methods of above-mentioned diol type ginsenoside nano-emulsion, include the following steps:
(a) blended emulsifier being made of sorbester p17 and 1,2-PD is added in oily phase according to the proportion, at 40 DEG C
Heating condition under be stirred with the revolving speed of 650~1300r/min, obtain the mixed solution of clear state；
(b) diol type ginseng ginseng saponin extract is dissolved in water and obtains water phase, water phase is added dropwise to what step (a) obtained
In mixed solution, stir evenly.
In the above-mentioned technical solutions, in step (b), by water phase under the revolving speed stirring of 40 DEG C, 650~1300r/min
It is added dropwise in the mixed solution that step (a) obtains.
The present invention also provides a kind of cosmetic composition for anti aging effect, the composition includes above-mentioned glycol
Type ginsenoside nano-emulsion.The composition can also include the acceptable auxiliary material of cosmetics, type for the auxiliary material and
Usage amount can use the auxiliary material and usage amount of this field routine as needed without being particularly limited to, and can be prepared
The cosmetic composition with anti aging effect containing above-mentioned diol type ginsenoside nano-emulsion.The cosmetic composition can
Think liquid-type, emulsion-type, cream type cosmetics and facial mask class cosmetology skin care item.
Beneficial effects of the present invention:
W/o type nano-emulsion is made in diol type ginsenoside by the present invention, and diol type ginsenoside soluble easily in water is wrapped up
In inner aqueous phase, surface is oily phase, and this considerably increases the compatibilities of emulsion and skin, and since emulsion partial size is in Nano grade,
The performance for passing it through skin dramatically increases, and has certain protective effect and slow releasing function to diol type ginsenoside,
Significantly improve its anti aging effect function.It extracts to obtain the diol type ginseng as active constituent using buck ultrasonic extraction
Saponin extract, wherein diol type ginsenoside Rb1, Rb2, Rc, the sum of content of Rd is not less than 38%.The present invention uses constant temperature
Low-energy emulsification method prepares nano-emulsion, and preparation process is easy, and quality is easily controllable.
Detailed description of the invention
Fig. 1 is diol type ginsenoside extract dry product HPLC chromatogram.
Fig. 2 is the particle diameter measurements of diol type ginsenoside nano-emulsion.
Fig. 3 is that the skin of diol type ginsenoside nano-emulsion adds up transit dose result.
Fig. 4 is the skin hold-up result of diol type ginsenoside nano-emulsion.
Fig. 5 is the hydroxyproline content measurement result of diol type ginsenoside nano-emulsion each group.
Fig. 6 is the type i collagen assay result of diol type ginsenoside nano-emulsion each group.
Fig. 7 is the type III Contents of collagen result of diol type ginsenoside nano-emulsion each group.
Fig. 8 is the TIMP-1 assay result of diol type ginsenoside nano-emulsion each group.
Fig. 9 is the TIMP-2 assay result of diol type ginsenoside nano-emulsion each group.
Figure 10 is the MMP-1 assay result of diol type ginsenoside nano-emulsion each group.
Specific embodiment
Present invention will be described in further detail below with reference to the accompanying drawings and specific embodiments, but the present invention does not limit to
In these embodiments.In following embodiments, unless otherwise specified, used experimental method is conventional method, material used
Material, reagent etc. can be bought from biological or chemical company.
Ginseng coarse powder: 5 years raw dry ginsengs crush, powder crosses No. four sieves, about 250 μm of partial size of coarse powder obtained, for mentioning
It takes.
Embodiment 1
Diol type ginsenoside extract is prepared as follows to obtain:
(1) by the Ca (OH) of ginseng coarse powder and pH=132Aqueous solution is mixed in the ratio of solid-liquid ratio=1:10 (g:mL),
Extracting temperature is 20 DEG C, and ultrasonic extraction power is 160w, is extracted under conditions of extraction time 20min, will after the completion of extracting
Drug residue filter obtains ginsenoside extracting solution；Extracting solution filtering, filtrate are concentrated into medicinal extract, and the dissolution of 80% ethyl alcohol, filtering is added
Ginsenoside filtrate is obtained, the concentration of ginsenoside filtrate removes ethyl alcohol, and distilled water dissolution is added, obtains ginsenoside aqueous solution；
(2) macroporous absorbent resin (D101, Sinopharm Chemical Reagent Co., Ltd.) is fitted into splitter, and pillar is washed with water
To macroporous absorbent resin without alcohol taste, ginsenoside aqueous solution wet process upper prop, flow velocity is 0.2mL per second, with 4 times after standing 2 hours
Column volume washes column, to remove most of impurity, then with 3 times of 35% ethanol elutions of column volume, removes three alcohol type ginsenosides
With small part impurity, then with 3 times of 85% ethanol elutions of column volume, 85% ethanol eluate is collected；
(3) by 85% ethanol eluate, ethyl alcohol is recycled, concentrate is freeze-dried 72h at -20 DEG C, and diol type people is made
Join saponin extract dry product.
Dry product 500mg is taken, 50mL methanol is added, ultrasonic dissolution obtains 10mg/mL solution.It is detected with HPLC method, detection side
Method: chromatographic column Hypersil Gold C18 (250mm × 4.6 μm, 5 μm), Detection wavelength 203nm, sample volume are 10 μ L, column
Temperature is 40 DEG C, flow velocity 1.000mL/min, gradient elution such as the following table 1:
1 gradient elution table of table
Testing result such as Fig. 1 can be obtained by the calculating of peak value and be contained diol type ginsenoside Rb in dry product1, Rb2, Rc,
Rd, the sum of content are about 42%.
Embodiment 2
With the raw material for the diol type ginsenoside extract that embodiment 1 is prepared, diol type ginsenoside nanometer is prepared
Cream, the preparation method is as follows:
(1) sorbester p17 and 1,2-PD 2:1 in mass ratio mix to obtain blended emulsifier, (i.e. by isopropyl palmitate
Oily phase) it is mixed with blended emulsifier according to mass ratio 7.5:2.5, under 40 DEG C of heating condition, with magnetic stirring apparatus with revolving speed
The rate of 650r/min is stirred, and stirring to mixed solution is in clear state, obtains mixed solution；
(2) diol type ginsenoside extract is dissolved in water and obtains water phase, under 40 DEG C of heating condition, with magnetic stirring apparatus with
Under conditions of the rate stirring of revolving speed 650r/min, water phase is added dropwise to oil mutually and in the mixed solution of blended emulsifier,
Mixed system is stopped being added dropwise, is obtained diol type ginsenoside nano-emulsion by clarifying the critical point become cloudy.
Wherein, mass concentration of the diol type ginsenoside extract in water phase is 200mg/mL；The water phase and oily phase
Mass ratio be 8:45.
Embodiment 3
With the raw material for the diol type ginsenoside extract that embodiment 1 is prepared, diol type ginsenoside nanometer is prepared
Cream, the preparation method is as follows:
(1) sorbester p17 and 1,2-PD 2:1 in mass ratio mix to obtain blended emulsifier, by isopropyl myristate
(i.e. oily phase) is mixed with blended emulsifier according to mass ratio 7.5:2.5, under 40 DEG C of heating condition, with magnetic stirring apparatus to turn
The rate of fast 650r/min is stirred, and stirring to mixed solution is in clear state, obtains mixed solution；
(2) diol type ginsenoside extract is dissolved in water and obtains water phase, under 40 DEG C of heating condition, with magnetic stirring apparatus with
Under conditions of the rate stirring of revolving speed 650r/min, water phase is added dropwise to oil mutually and in the mixed solution of blended emulsifier,
Mixed system is stopped being added dropwise, is obtained diol type ginsenoside nano-emulsion by clarifying the critical point become cloudy.
Wherein, mass concentration of the diol type ginsenoside extract in water phase is 200mg/mL；The water phase and oily phase
Mass ratio be 8:45.
Embodiment 4
With the raw material for the diol type ginsenoside extract that embodiment 1 is prepared, diol type ginsenoside nanometer is prepared
Cream, the preparation method is as follows:
(1) sorbester p17 and PEG400 2:1 in mass ratio mix to obtain blended emulsifier, by isopropyl palmitate (i.e. oily phase)
It is mixed with blended emulsifier according to mass ratio 7.5:2.5, under 40 DEG C of heating condition, with magnetic stirring apparatus with revolving speed 650r/
The rate of min is stirred, and stirring to mixed solution is in clear state, obtains mixed solution；
(2) diol type ginsenoside extract is dissolved in water and obtains water phase, under 40 DEG C of heating condition, with magnetic stirring apparatus with
Under conditions of the rate stirring of revolving speed 650r/min, water phase is added dropwise to oil mutually and in the mixed solution of blended emulsifier,
Mixed system is stopped being added dropwise, is obtained diol type ginsenoside nano-emulsion by clarifying the critical point become cloudy.
Wherein, mass concentration of the diol type ginsenoside extract in water phase is 200mg/mL；The water phase and oily phase
Mass ratio be 8:45.
Embodiment 5
With the raw material for the diol type ginsenoside extract that embodiment 1 is prepared, diol type ginsenoside nanometer is prepared
Cream, the preparation method is as follows:
(1) sorbester p17 and 1,2-PD 3:1 in mass ratio mix to obtain blended emulsifier, (i.e. by isopropyl palmitate
Oily phase) it is mixed with blended emulsifier according to mass ratio 7.5:2.5, under 40 DEG C of heating condition, with magnetic stirring apparatus with revolving speed
The rate of 650r/min is stirred, and stirring to mixed solution is in clear state, obtains mixed solution；
(2) diol type ginsenoside extract is dissolved in water and obtains water phase, under 40 DEG C of heating condition, with magnetic stirring apparatus with
Under conditions of the rate stirring of revolving speed 650r/min, water phase is added dropwise to oil mutually and in the mixed solution of blended emulsifier,
Mixed system is stopped being added dropwise, is obtained diol type ginsenoside nano-emulsion by clarifying the critical point become cloudy.
Wherein, mass concentration of the diol type ginsenoside extract in water phase is 200mg/mL；The water phase and oily phase
Mass ratio be 8:45.
Embodiment 6
With the raw material for the diol type ginsenoside extract that embodiment 1 is prepared, diol type ginsenoside nanometer is prepared
Cream, the preparation method is as follows:
(1) sorbester p17 and 1,2-PD 1:1 in mass ratio mix to obtain blended emulsifier, (i.e. by isopropyl palmitate
Oily phase) it is mixed with blended emulsifier according to mass ratio 7.5:2.5, under 40 DEG C of heating condition, with magnetic stirring apparatus with revolving speed
The rate of 650r/min is stirred, and stirring to mixed solution is in clear state, obtains mixed solution；
(2) diol type ginsenoside extract is dissolved in water and obtains water phase, under 40 DEG C of heating condition, with magnetic stirring apparatus with
Under conditions of the rate stirring of revolving speed 650r/min, water phase is added dropwise to oil mutually and in the mixed solution of blended emulsifier,
Mixed system is stopped being added dropwise, is obtained diol type ginsenoside nano-emulsion by clarifying the critical point become cloudy.
Wherein, mass concentration of the diol type ginsenoside extract in water phase is 200mg/mL；The water phase and oily phase
Mass ratio be 8:45.
Embodiment 7
With the raw material for the diol type ginsenoside extract that embodiment 1 is prepared, diol type ginsenoside nanometer is prepared
Cream, the preparation method is as follows:
(1) sorbester p17 mixes to obtain blended emulsifier with 1,2-PD 2:1 in mass ratio, and isopropyl palmitate is (i.e. oily
Phase) it is mixed with blended emulsifier according to mass ratio 8:2, under 40 DEG C of heating condition, with magnetic stirring apparatus with revolving speed 650r/
The rate of min is stirred, and stirring to mixed solution is in clear state, obtains mixed solution；
(2) diol type ginsenoside extract is dissolved in water and obtains water phase, under 40 DEG C of heating condition, with magnetic stirring apparatus with
Under conditions of the rate stirring of revolving speed 650r/min, water phase is added dropwise to oil mutually and in the mixed solution of blended emulsifier,
Mixed system is stopped being added dropwise, is obtained diol type ginsenoside nano-emulsion by clarifying the critical point become cloudy.
Wherein, mass concentration of the diol type ginsenoside extract in water phase is 200mg/mL；The water phase and oily phase
Mass ratio be 1:6.
Embodiment 8
With the raw material for the diol type ginsenoside extract that embodiment 1 is prepared, diol type ginsenoside nanometer is prepared
Cream, the preparation method is as follows:
(1) sorbester p17 mixes to obtain blended emulsifier with 1,2-PD 2:1 in mass ratio, and isopropyl palmitate is (i.e. oily
Phase) it is mixed with blended emulsifier according to mass ratio 7.5:2.5, under 30 DEG C of heating condition, with magnetic stirring apparatus with revolving speed
The rate of 650r/min is stirred, and stirring to mixed solution is in clear state, obtains mixed solution；
(2) diol type ginsenoside extract is dissolved in water and obtains water phase, under 30 DEG C of heating condition, with magnetic stirring apparatus with
Under conditions of the rate stirring of revolving speed 650r/min, water phase is added dropwise to oil mutually and in the mixed solution of blended emulsifier,
Mixed system is stopped being added dropwise, is obtained diol type ginsenoside nano-emulsion by clarifying the critical point become cloudy.
Wherein, mass concentration of the diol type ginsenoside extract in water phase is 200mg/mL；The water phase and oily phase
Mass ratio be 8:45.
Embodiment 9
With the raw material for the diol type ginsenoside extract that embodiment 1 is prepared, diol type ginsenoside nanometer is prepared
Cream, the preparation method is as follows:
(1) sorbester p17 mixes to obtain blended emulsifier with 1,2-PD 2:1 in mass ratio, and isopropyl palmitate is (i.e. oily
Phase) it is mixed with blended emulsifier according to mass ratio 7.5:2.5, under 40 DEG C of heating condition, with magnetic stirring apparatus with revolving speed
The rate of 1300r/min is stirred, and stirring to mixed solution is in clear state, obtains mixed solution；
(2) diol type ginsenoside extract is dissolved in water and obtains water phase, under 40 DEG C of heating condition, with magnetic stirring apparatus with
Under conditions of the rate stirring of revolving speed 1300r/min, water phase is added dropwise to oil mutually and in the mixed solution of blended emulsifier,
Mixed system is stopped being added dropwise, is obtained diol type ginsenoside nano-emulsion by clarifying the critical point become cloudy.
Wherein, mass concentration of the diol type ginsenoside extract in water phase is 200mg/mL；The water phase and oily phase
Mass ratio be 8:45.
Embodiment 10
With the raw material for the diol type ginsenoside extract that embodiment 1 is prepared, diol type ginsenoside nanometer is prepared
Cream, the preparation method is as follows:
(1) sorbester p17 mixes to obtain blended emulsifier with 1,2-PD 2:1 in mass ratio, and isopropyl palmitate is (i.e. oily
Phase) it is mixed with blended emulsifier according to mass ratio 7.5:2.5, under 40 DEG C of heating condition, with magnetic stirring apparatus with revolving speed
The rate of 650r/min is stirred, and stirring to mixed solution is in clear state, obtains mixed solution；
(2) diol type ginsenoside extract is dissolved in water and obtains water phase, under 40 DEG C of heating condition, with magnetic stirring apparatus with
Under conditions of the rate stirring of revolving speed 650r/min, water phase is added dropwise to oil mutually and in the mixed solution of blended emulsifier,
Mixed system is stopped being added dropwise, is obtained diol type ginsenoside nano-emulsion by clarifying the critical point become cloudy.
Wherein, mass concentration of the diol type ginsenoside extract in water phase is 250mg/mL；The water phase and oily phase
Mass ratio be 8:45.
The measurement of 11 diol type ginsenoside nano-emulsion particle diameter of embodiment
The diol type ginsenoside nano-emulsion for taking appropriate embodiment 2 to be prepared is placed in testing graininess ware, uses Zeta
Current potential particle size analyzer (manoBrook 90plus zeta, Brookhaven) carries out particle size determination to it, measures 3 times.Measurement
As a result such as Fig. 2, Fig. 2 meets nano-emulsion granularity requirements as it can be seen that diol type ginsenoside nano-emulsion average grain diameter is 17.4nm.
The measurement of 12 diol type ginsenoside nano-emulsion vitro cumulative transit dose of embodiment
Six adult male mices are taken, are randomly divided into two groups, every group three, respectively diol type ginsenoside nano-emulsion
(embodiment 2 is prepared) group and diol type ginsenoside aqueous solution group.Mouse part skin is taken, Transdermal diffusion cell is fixed on,
It is 4.2mg/mL ginsenoside nano-emulsion and 4.2mg/mL ginsenoside aqueous solution that two groups are administered 3mL concentration respectively.Receiving liquid is
PBS phosphate buffer is sampled in 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, amount of sampling 2mL, supplements 2mL after sampling every time
PBS phosphate buffer, receiving liquid of sampling every time carry out high performance liquid chromatography measurement, calculate two groups of diol type ginsenoside units
Skin area adds up transit dose.
Transit dose mapping is added up to nano-emulsion group and aqueous solution group unit skin respectively, as a result such as Fig. 3, it is seen then that nano-emulsion
Group diol type ginsenoside transit dose is apparently higher than aqueous solution group, shows that diol type ginsenoside nano-emulsion can effectively penetrate skin
Skin has good percutaneous abilities.
The measurement of 13 diol type ginsenoside nano-emulsion skin hold-up of embodiment
In embodiment 11, mouse skin after every group of administration 12h is taken, blank receiving liquid rinse off skin remained on surface drug,
Fixed clip medicine-feeding part skin, shreds, and is homogenized with tissue homogenizer, adds 2mL PBS phosphate buffer ultrasonic extraction 20min,
8000r/min centrifugation 15min takes supernatant, carries out efficient liquid phase measurement, calculates and be detained diol type content of ginsenoside in skin.
As a result such as Fig. 4, it is seen then that the diol type ginsenoside skin hold-up of nano-emulsion group is significantly higher than aqueous solution group, this
Diol type ginsenoside can be detained in skin part after meaning nano-emulsion percutaneous drug delivery, there is certain slow releasing function, be extended
Drug treating time improves bioavilability.
14 diol type ginsenoside nano-emulsion anti aging effect zoopery of embodiment
It studies the influence of diol type ginsenoside nano-emulsion (preparation of embodiment 2) to collagen content in skin: taking into
Year male mice 30, back depilation are divided into six groups, are divided into ginsenoside nano-emulsion high dose group (1.54mg/mL), people
Join saponin(e nano-emulsion middle dose group (0.77mg/mL), ginsenoside nano-emulsion low dose group (0.38mg/mL), ginsenoside water
Solution group (0.77mg/mL), blank nano-emulsion group, positive controls (the five compact frost of precious moisturizing of skin makeup treasured).
Every group of mouse is smeared daily to be administered once, and every is administered 0.2mL every time, and successive administration 4 weeks, it is small to record each group weekly
Mouse changes of weight, the 4th week execution mouse, takes back medicine-feeding part skin, -40 DEG C freeze.
Every group of every mouse skin 0.5g is respectively weighed, is shredded, is added in homogenate tube, adds 9 times of amount 0.01mmol PBS
Buffer is homogenized with interior cut type tissue homogenizer, and 10% homogenate is made, and every pipe homogenate crushes 1min with cell pulverization instrument,
It is centrifuged 10min in 8000r/min centrifuge, takes supernatant, is frozen.
Hydroxyproline in supernatant, type i collagen, type III collagen, matrix gold are detected respectively by ELisa kit specification
Proteases -1 (MMP-1), matrix metalloproteinase inhibitors -1 (TIMP-1), Tissue inhibitor of metalloproteinase-2
(TIMP-2) content.
As a result such as Fig. 5~10, ginsenoside nano-emulsion group can be dramatically increased compared with other groups hydroxyproline, type i collagen,
Type III collagen content inhibits the matrix metalloproteinase inhibitors -1 (TIMP-1) and matrix metalloproteinase of decomposition of collagen
Inhibiting factor -2 (TIMP-2) significantly increases, and the Fibroblast collagenase (MMP-1) of decomposition of collagen is promoted to reduce.The above index
And show dose dependent.It can be seen that diol type ginsenoside nano-emulsion can be promoted by activating collagen regulatory factor
It is synthesized into skin collagen, collagenase activity is inhibited to achieve the purpose that anti aging effect.
The preferred embodiment of the present invention has been described in detail above, but the invention be not limited to it is described
Embodiment, those skilled in the art can also make various equivalent on the premise of not violating the inventive spirit of the present invention
Variation or replacement, these equivalent variation or replacement are all included in the scope defined by the claims of the present application.
Claims (9)
1. a kind of diol type ginsenoside nano-emulsion, which is characterized in that be grouped as by following group: being extracted by diol type ginsenoside
The water phase of object and water composition, oil phase and blended emulsifier；Wherein, the mass ratio of the water phase and oily phase is 5~8:45, the oil
Mutually and the mass ratio of blended emulsifier is 7.5~8:2~2.5, quality of the diol type ginsenoside extract in water phase
Concentration is 15~25%, the diol type ginsenoside Rb that the diol type ginsenoside extract contains1、Rb2, Rc and Rd contain
The sum of amount is not less than 38%.
2. diol type ginsenoside nano-emulsion according to claim 1, which is characterized in that the oil is mutually palmitinic acid isopropyl
Ester or isopropyl myristate, the blended emulsifier are arranged to by sorbester p17 and 1,2-PD 3:1~3 in mass ratio
It arrives.
3. diol type ginsenoside nano-emulsion according to claim 1, which is characterized in that the diol type ginsenoside mentions
The preparation method of object is taken to include the following steps:
(1) Ca (OH) for being 11~13 by ginseng coarse powder and pH2Aqueous solution is mixed in the ratio of solid-liquid ratio g:mL=1:10~15,
It is 20 DEG C~35 DEG C in Extracting temperature, is extracted under conditions of ultrasonic power 120w~160w, extracting solution filtering obtains ginseng soap
Glycosides extracting solution；
(2) the ginsenoside extracting solution for obtaining step (1) is first eluted with water by large pore resin absorption column, then uses volume
The ethanol gradient elution that percentage concentration is 35%~85%, collects eluent, and concentration, freeze-drying obtain diol type ginsenoside
Extract.
4. diol type ginsenoside nano-emulsion according to claim 2, which is characterized in that the diol type ginsenoside mentions
The preparation method of object is taken to include the following steps:
(1) Ca (OH) for being 13 by ginseng coarse powder and pH2Aqueous solution is mixed in the ratio of solid-liquid ratio g:mL=1:10, is extracting temperature
Degree is 20 DEG C, is extracted under conditions of ultrasonic power 160w, and extracting solution filtering obtains ginsenoside extracting solution；
(2) the ginsenoside extracting solution for obtaining step (1) is by large pore resin absorption column, with the washing of 3~6 times of column volumes
De-, then successively with 35% ethyl alcohol of 3~6 times of column volumes, 85% ethanol elution of 3~6 times of column volumes, 85% ethyl alcohol of collection is washed
De- liquid, concentration, freeze-drying, obtains diol type ginsenoside extract.
5. the preparation method of described in any item diol type ginsenoside nano-emulsions of Claims 1 to 4, includes the following steps:
(a) blended emulsifier being made of sorbester p17 and 1,2-PD is added in oily phase according to the proportion, in 40 DEG C add
It is stirred under heat condition with the revolving speed of 650~1300r/min, obtains the mixed solution of clear state；
(b) diol type ginsenoside extract is dissolved in water and obtains water phase, it is molten that water phase is added dropwise to the mixing that step (a) obtains
In liquid, stir evenly.
6. preparation method according to claim 5, which is characterized in that in step (b), in 40 DEG C, 650~1300r/
Water phase is added dropwise in the mixed solution that step (a) obtains under the revolving speed stirring of min.
7. a kind of cosmetic composition for anti aging effect, it includes described in any item diol types of Claims 1 to 4
Ginsenoside nano-emulsion.
8. cosmetic composition according to claim 7, which is characterized in that further include the acceptable auxiliary material of cosmetics.
9. cosmetic composition according to claim 7 or 8, which is characterized in that the cosmetic composition liquid-type, cream
Liquid type, cream type cosmetics and facial mask class.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811282724.4A CN109223582A (en) | 2018-10-31 | 2018-10-31 | Diol type ginsenoside nano-emulsion with anti aging effect function and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811282724.4A CN109223582A (en) | 2018-10-31 | 2018-10-31 | Diol type ginsenoside nano-emulsion with anti aging effect function and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109223582A true CN109223582A (en) | 2019-01-18 |
Family
ID=65079740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811282724.4A Pending CN109223582A (en) | 2018-10-31 | 2018-10-31 | Diol type ginsenoside nano-emulsion with anti aging effect function and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109223582A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113730279A (en) * | 2021-09-23 | 2021-12-03 | 茵素科技(广州)有限公司 | Night skin care composition, and composition for regulating skin circadian rhythm |
| CN117442522A (en) * | 2023-11-23 | 2024-01-26 | 云南贝泰妮生物科技集团股份有限公司 | A high-content, high-stability ginsengdiol preparation and its preparation method and application |
| CN117660579A (en) * | 2023-12-12 | 2024-03-08 | 中科药创(青岛)发酵工程有限公司 | Dual-drug-effect cordyceps militaris solid-state fermentation ginseng product and preparation method thereof |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1327434A1 (en) * | 2002-01-05 | 2003-07-16 | Pacific Corporation | Nanoemulsion comprising metabolites of ginseng saponin and a skin-care composition for anti-aging containing the same |
| CN1626104A (en) * | 2003-08-25 | 2005-06-15 | 山东绿叶天然药物研究开发有限公司 | Nano emulsion of containing ginsenoside, preparation method and usage |
| CN1931122A (en) * | 2006-09-18 | 2007-03-21 | 西北农林科技大学 | Nanometer skin-activating emulsion cosmetics and its prepn process |
| CN102743402A (en) * | 2012-07-15 | 2012-10-24 | 浙江大学 | Application of panaxadiol saponins fraction in preparing medicine for preventing dermatitis and scar |
| KR20130003944A (en) * | 2011-07-01 | 2013-01-09 | 주식회사 바이오랜드 | Methods for preparing fermented ginseng extracts |
| CN103070898A (en) * | 2013-01-29 | 2013-05-01 | 广东药学院 | Salvia miltiorrhiza and panax notoginseng compound nano suspension |
| CN103271960A (en) * | 2013-06-20 | 2013-09-04 | 敦化市广晟油脂生物科技有限责任公司 | Preparation method of ginseng cream richly containing scare ginsenosides Rg3 and Rh2 |
| CN103271891A (en) * | 2013-04-28 | 2013-09-04 | 福建南方制药股份有限公司 | Ginsenoside nano-micelle, and preparation method, application and pharmaceutical composition thereof |
| CN103381142A (en) * | 2012-05-04 | 2013-11-06 | 上海现代药物制剂工程研究中心有限公司 | Ginsenoside Rh1 self-microemulsion composition, and preparation method and application thereof |
| CN103462846A (en) * | 2013-09-17 | 2013-12-25 | 吉林大学 | Ginseng-based whitening and anti-aging nanoemulsion essence and preparation method thereof |
| CN105769955A (en) * | 2015-01-09 | 2016-07-20 | 株式会社爱茉莉太平洋 | Composition comprising ginseng extracts with enhanced ginsenoside contents |
| CN108143650A (en) * | 2018-03-05 | 2018-06-12 | 桂林医学院 | A kind of anti-aging Essence and preparation method thereof |
-
2018
- 2018-10-31 CN CN201811282724.4A patent/CN109223582A/en active Pending
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1327434A1 (en) * | 2002-01-05 | 2003-07-16 | Pacific Corporation | Nanoemulsion comprising metabolites of ginseng saponin and a skin-care composition for anti-aging containing the same |
| CN1626104A (en) * | 2003-08-25 | 2005-06-15 | 山东绿叶天然药物研究开发有限公司 | Nano emulsion of containing ginsenoside, preparation method and usage |
| CN1931122A (en) * | 2006-09-18 | 2007-03-21 | 西北农林科技大学 | Nanometer skin-activating emulsion cosmetics and its prepn process |
| KR20130003944A (en) * | 2011-07-01 | 2013-01-09 | 주식회사 바이오랜드 | Methods for preparing fermented ginseng extracts |
| CN103381142A (en) * | 2012-05-04 | 2013-11-06 | 上海现代药物制剂工程研究中心有限公司 | Ginsenoside Rh1 self-microemulsion composition, and preparation method and application thereof |
| CN102743402A (en) * | 2012-07-15 | 2012-10-24 | 浙江大学 | Application of panaxadiol saponins fraction in preparing medicine for preventing dermatitis and scar |
| CN103070898A (en) * | 2013-01-29 | 2013-05-01 | 广东药学院 | Salvia miltiorrhiza and panax notoginseng compound nano suspension |
| CN103271891A (en) * | 2013-04-28 | 2013-09-04 | 福建南方制药股份有限公司 | Ginsenoside nano-micelle, and preparation method, application and pharmaceutical composition thereof |
| CN103271960A (en) * | 2013-06-20 | 2013-09-04 | 敦化市广晟油脂生物科技有限责任公司 | Preparation method of ginseng cream richly containing scare ginsenosides Rg3 and Rh2 |
| CN103462846A (en) * | 2013-09-17 | 2013-12-25 | 吉林大学 | Ginseng-based whitening and anti-aging nanoemulsion essence and preparation method thereof |
| CN105769955A (en) * | 2015-01-09 | 2016-07-20 | 株式会社爱茉莉太平洋 | Composition comprising ginseng extracts with enhanced ginsenoside contents |
| CN108143650A (en) * | 2018-03-05 | 2018-06-12 | 桂林医学院 | A kind of anti-aging Essence and preparation method thereof |
Non-Patent Citations (8)
| Title |
|---|
| 刘梦娜等: "人参皂苷抗皮肤光老化作用的新进展", 《南昌大学学报（医学版）》 * |
| 史作清等: "《吸附分离树脂在医药工业中的应用》", 30 September 2008, 化学工业出版社 * |
| 张春红等: "人参皂苷常规水提取法和新提取方法的比较研究", 《中药材》 * |
| 李金燕等: "人参皂苷Rb1对皮肤胶原代谢的影响", 《海峡药学》 * |
| 李骏飞等: "人参皂苷Rg1、Rb1及Re对人皮肤胶原代谢作用的研究", 《同济大学学报（医学版）》 * |
| 梁敬钰: "《天然药物化学实验与指导》", 31 August 2003, 中国医药科技出版社 * |
| 钟桂书等: "雷公藤、人参与芳维甲酸乙酯对培养光老化真皮成纤维细胞的影响", 《中国组织工程研究与临床康复》 * |
| 顾绝奋: "《离子交换与吸附树脂在制药工业上的应用》", 30 April 2008, 中国医药科技出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113730279A (en) * | 2021-09-23 | 2021-12-03 | 茵素科技(广州)有限公司 | Night skin care composition, and composition for regulating skin circadian rhythm |
| CN117442522A (en) * | 2023-11-23 | 2024-01-26 | 云南贝泰妮生物科技集团股份有限公司 | A high-content, high-stability ginsengdiol preparation and its preparation method and application |
| CN117660579A (en) * | 2023-12-12 | 2024-03-08 | 中科药创(青岛)发酵工程有限公司 | Dual-drug-effect cordyceps militaris solid-state fermentation ginseng product and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101444470B (en) | Use of oligosaccharides to stimulate beta-endorphin production | |
| CN110882201B (en) | Itching-relieving skin-care cream and preparation method thereof | |
| CN109223582A (en) | Diol type ginsenoside nano-emulsion with anti aging effect function and preparation method thereof | |
| JP2006111560A (en) | Ceramide synthesis promoter | |
| CN112569151B (en) | Anti-allergy repairing barrier composition and preparation method and application thereof | |
| CN112569152B (en) | Oil-control anti-inflammatory plant combined extract and preparation method and application thereof | |
| CN101239030A (en) | Red ginseng extract preparation and skin-protection product development thereof | |
| CN1943546B (en) | Cosmetics containing natural transdermal imported agent and its preparing method | |
| CN106265164A (en) | There is compositions of hair growth promoting, scalp maintenance, moisture-keeping efficacy and preparation method thereof | |
| CN101433666B (en) | Anti-aging Chinese herbal medicinal composition, preparation method and use thereof | |
| CN113018202A (en) | Dendrobium officinale polysaccharide/astragalus polysaccharide composite hydrogel as well as preparation method and application thereof | |
| CN103751552B (en) | A kind of Chinese medicine composition and preparation method and application with senile-resistant efficacy | |
| CN103315926A (en) | Chinese medicinal facial mask possessing efficacies on removing spots and smoothing crease, and preparation method thereof | |
| CN109549881A (en) | A kind of preparation method of composite plant anti-shed hair growth liquid | |
| KR101747111B1 (en) | Cosmetic composition for protecting scalp and hair comprising wood cultivated ginseng extract | |
| CN101695563A (en) | Particles and powders for preventing and treating chronic bronchitis and cor pulmonale | |
| CN105769727A (en) | Whitening skin-care product containing sea cucumber decoction extract and preparation method of whitening skin-care product | |
| CN104382801A (en) | Kandelia candel leaf total flavonoid nano-emulsion for whitening skin and removing freckles and gel thereof | |
| CN109293726A (en) | Diol-type ginsenoside extract and preparation method thereof | |
| CN102085170A (en) | Nano-meter pearl and sanchi mask cream and preparation method | |
| JP3973912B2 (en) | Skin external preparation for hair growth comprising an extract of a herbal medicine having a tsuyu action and a herbal extract having angiogenic activity | |
| CN108403532B (en) | A kind of skin conditioner comprising ginseng extract | |
| JP3441395B2 (en) | Endothelin converting enzyme inhibitor | |
| CN117653580B (en) | Herba Lophatheri extract, and its preparation method and application in cosmetics | |
| CN108030813A (en) | A kind of clarification process and method of quality control of the pharmaceutical composition with delay skin aging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190118 |
|
| WD01 | Invention patent application deemed withdrawn after publication |